High-dose vitamin B3 may enhance immune function and slow the progression of glioblastoma, with 82% of trial patients showing no disease progression after six months, according to a recent study.
High-dose vitamin B3, commonly known as niacin, may significantly boost immune function and improve short-term disease control in patients with glioblastoma when used alongside standard therapies, according to early preclinical studies.
Glioblastoma is a highly aggressive and fast-growing brain cancer that originates from cells in the brain and spinal cord. Previous laboratory experiments conducted on mice indicated that niacin could extend survival rates. Researchers at the University of Calgary sought to determine whether these benefits could also be observed in humans.
The clinical trial included 24 patients diagnosed with glioblastoma, a condition that typically has a median survival rate of approximately 12 to 18 months. Remarkably, six months after receiving niacin in conjunction with standard treatments—surgery, radiation, and chemotherapy—82% of the patients exhibited no disease progression. This is a notable increase compared to the typical 54% of patients who experience no progression under standard treatment alone, as reported in the study’s press release.
Additionally, niacin was found to restore functionality in weakened immune cells, enhancing their ability to target and eliminate tumor cells. The findings, which highlight a 28% improvement in disease progression, were published in the Journal of Neuro-Oncology.
“Normally, the immune system attempts to counter and prevent tumor growth; however, glioblastoma actively suppresses the immune response,” said Dr. Wee Yong, PhD, a neuroscientist involved in the study. “Niacin treatment rejuvenates immune cells so they can perform their essential functions: attacking and destroying cancer cells. I view this as an ongoing ‘battle for the brain.’”
Looking ahead, the research team plans to enroll an additional 24 patients by the end of 2026 or early 2027 for the next phase of the trial, which will focus on assessing niacin’s safety and its effects on immune system activation.
Dr. Marc Siegel, a senior medical analyst at Fox News, noted that previous studies have demonstrated that vitamin B3 can reduce inflammation and enhance immune function. “Vitamins, including the B vitamins—especially niacin—are often underrecognized as immune boosters,” he stated, although he was not involved in the study.
Despite these promising early results, the researchers have urged caution regarding the implications of their findings. “Glioblastoma is the most aggressive brain cancer in adults, and patient survival rates have not significantly improved in the past two decades,” said lead study author Roldan Urgoiti, a clinical associate professor at the CSM. “While any potential treatment that may help should be explored, it requires strict protocols and safety monitoring.”
The study’s limitations include its small sample size, short follow-up period, and the absence of a randomized control group. The researchers emphasized the need for larger, controlled trials to verify their findings.
Furthermore, the researchers cautioned that high doses of vitamins can pose health risks, and any supplementation should be closely monitored by healthcare professionals. Dr. Siegel also acknowledged that niacin can have side effects, such as skin flushing. “While there may be a small impact here, this information is useful, though it is clearly not a cure,” he added.
As the research progresses, the scientific community remains hopeful that niacin could play a role in enhancing treatment options for glioblastoma patients, but further investigation is essential to fully understand its potential benefits and risks.
According to Fox News, the ongoing exploration of vitamin therapies in cancer treatment represents a promising avenue for improving patient outcomes in the face of challenging diagnoses.